SI-BONE, Inc. (SIBN) |
| 21.23 -1.18 (-5.27%) 10-30 16:00 |
| Open: | 22.185 |
| High: | 22.25 |
| Low: | 20.95 |
| Volume: | 1,249,176 |
| Market Cap: | 951(M) |
| PE Ratio: | -62.44 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 26.79 |
| Resistance 1: | 22.94 |
| Pivot price: | 20.74 |
| Support 1: | 19.86 |
| Support 2: | 17.95 |
| 52w High: | 22.95 |
| 52w Low: | 11.48 |
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
| EPS | -0.340 |
| Book Value | 4.080 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.790 |
| Profit Margin (%) | -6.85 |
| Operating Margin (%) | -8.58 |
| Return on Assets (ttm) | -4.6 |
| Return on Equity (ttm) | -8.3 |
Thu, 29 Oct 2026
SI-BONE, Inc. (SIBN) Seasonal Returns Chart - Yahoo! Finance Canada
Thu, 29 Oct 2026
SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026 - GlobeNewswire
Fri, 23 Oct 2026
SI-BONE, Inc. Estimates – NASDAQ:SIBN - TradingView
Mon, 05 Oct 2026
Si-Bone director Jeffrey Dunn sells $369,400 in SIBN shares - Investing.com
Mon, 28 Sep 2026
SI-BONE Receives FDA 510(k) Clearance for iFuse Granite - GlobeNewswire
Mon, 28 Sep 2026
FDA clears a spinal fusion device for people with weak bones. It's SI-BONE's first such product for use beyond the pelvis. - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |